BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Trial Profile

BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical
  • Most Recent Events

    • 28 Jun 2018 Results published in the Biohaven Pharmaceutical Holding Company Media Release
    • 28 Jun 2018 According to a Biohaven Pharmaceutical Holding Company media release, data from this trial was presented at the the American Headache Society (AHS) Annual Scientific Meeting 2018.
    • 05 Jun 2018 According to a Biohaven Pharmaceutical Holding Company media release, expanded data will be presented at the American Headache Society (AHS) 60th Annual Scientific Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top